Aligos discontinues hepatitis B drug ALG-020572 after patient hospitalized with ALT flare

Aligos Therapeutics, Inc.

Discontinued ALG-020572 (ASO for chronic hepatitis B) after one subject hospitalized and three others experienced ALT flares following 210 mg multiple dosing.
Dosing in first CHB cohort of Study 401 stopped after serious adverse event (ALT increase, brief hospitalization).
All four affected subjects improving; hospitalized subject discharged. No further details on safety provided.
Cost savings from discontinuation to fund clinical and preclinical programs in CHB, NASH, and COVID-19.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.